O. Werner

Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial

R. Gelber, S. Loi, M. Piccart, 2019, Breast Cancer Research and Treatment.

Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials

D. Serie, E. Perez, E. Thompson, 2022, NPJ breast cancer.

Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial

M. Piccart, E. de Azambuja, O. Metzger-Filho, 2020, ESMO Open.

Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials

D. Serie, E. Perez, E. Thompson, 2022, npj Breast Cancer.

A five‐year follow‐up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial

A. Pettitt, A. Schuh, T. Robak, 2020, British journal of haematology.

Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D)

C. Sotiriou, R. Gelber, M. Piccart, 2020, Breast Cancer Research and Treatment.

Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial

M. Piccart, H. Gómez, I. Láng, 2020, British Journal of Cancer.